West China School of Medicine/West China Hospital, Sichuan University, Chengdu, China.
Department of Urology, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Ann Clin Lab Sci. 2020 Mar;50(2):161-171.
Increasing evidence suggested that inflammation is associated with the pathogenesis and progression of several solid tumors. This study was conducted to explore the association between C-reactive protein (CRP) and survival of prostate cancer (PCa). An electronic search was completed on the basis of PubMed, Embase and Cochrane Central Register of Controlled Trials. The hazard ratio (HR) and 95% confidence interval (CI) were extracted. Studies evaluating the relation between pretreatment levels of CRP and survival of PCa were included. Sixteen articles incorporating 17,833 patients were eligible for the present meta-analysis. Elevated pretreatment CRP level was significantly associated with poorer overall survival (OS) (HR=1.58, 95% CI 1.31-1.91, <0.001), cancer-specific survival (CSS) (HR=1.83, 95% CI 1.19-2.80, =0.006), progression-free survival (PFS) (HR=1.64, 95%CI 1.03-2.61, =0.036), and biochemical-recurrence free survival (BC-RFS) (HR=1.29, 95% CI 1.11-1.51, =0.001). Elevated pretreatment serum CRP level is strongly correlated with worse prognosis in patients with PCa, including OS, CSS, PFS and BC-RFS.
越来越多的证据表明，炎症与几种实体瘤的发病机制和进展有关。本研究旨在探讨 C 反应蛋白（CRP）与前列腺癌（PCa）患者生存的关系。基于 PubMed、Embase 和 Cochrane 对照试验中心注册库进行了电子检索。提取了危险比（HR）和 95%置信区间（CI）。纳入评估 CRP 术前水平与 PCa 患者生存关系的研究。共有 16 项研究纳入了 17833 名患者，符合本荟萃分析的条件。术前 CRP 水平升高与总体生存（OS）（HR=1.58，95%CI 1.31-1.91，<0.001）、癌症特异性生存（CSS）（HR=1.83，95%CI 1.19-2.80，=0.006）、无进展生存（PFS）（HR=1.64，95%CI 1.03-2.61，=0.036）和生化无复发生存（BC-RFS）（HR=1.29，95%CI 1.11-1.51，=0.001）显著相关。术前血清 CRP 水平升高与 PCa 患者的预后不良密切相关，包括 OS、CSS、PFS 和 BC-RFS。
